CN102772617B - Medicine for treating disease of hyperosteogeny - Google Patents
Medicine for treating disease of hyperosteogeny Download PDFInfo
- Publication number
- CN102772617B CN102772617B CN201210034160.9A CN201210034160A CN102772617B CN 102772617 B CN102772617 B CN 102772617B CN 201210034160 A CN201210034160 A CN 201210034160A CN 102772617 B CN102772617 B CN 102772617B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- radix
- hyperosteogeny
- achyranthis bidentatae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating the disease of hyperosteogeny. The medicine comprises the following pure traditional Chinese medicines according to parts by weight: 2 to 3 parts of safflower, 2 to 3 parts of speranskia tuberculata, 2 to 3 parts of lycopodium clavatum, 3 to 4 parts of angelica, 3 to 4 parts of twotooth achyranthes root, 3 to 4 parts of cassia twig, 3 to 4 parts of cibot rhizome, 3 to 4 parts of teasel root, 3 to 4 parts of prepared kusnezoff monkshood root, 3 to 4 parts of yam rhizome, 3 to 4 parts of radix gentianae macrophyllae, 3 to 4 parts of twotooth achyranthes root and 3 to 4 parts of fructus chaenomelis lagenariae. The medicine for treating the disease of the hyperosteogeny, which is disclosed by the invention, is prepared by the pure traditional Chinese medicines, has abundant medicine sources and is simple and convenient to prepare. Any other chemical substances are not added, the side effect is very small, the injury to a human body is very small after long-time taking, even no injury exists, and the treatment effect is obvious. Each important component in the medicine can be used for promoting the blood circulation to remove the blood stasis, dispelling wind, eliminating dampness, nourishing the liver and the kidney and strengthening muscles and bones so as to achieve the aim of treating the hyperosteogeny.
Description
Technical field
The present invention relates to a kind of medicine, specifically a kind of medicine for the treatment of bone matrix hyperplasia.
Background technology
It is a kind of degeneration of joint that bone matrix hyperplasia is again " bony spur ", is apt to occur in middle-older patient, is that skeleton certain part sclerotin in growth course loses normal morphology, and occurs extremely, such as: there is thorn-like, have lip shape, waveform, circle.Be apt to occur in: cervical vertebra, lumbar vertebra, hip, knee joint, ankle, calcaneus, upper limb are more common in elbow joint, interphalangeal joint.
Bone matrix hyperplasia is generally point four kinds of degree:
1 degree " bony spur " is less, at the upper lower limb of vertebral body, has little bone projection, but not obvious.
2 degree " bony spur " increase, and the osteocomma projection of edge up and down of vertebral body increases, and volume increases.
3 degree " bony spur " are beak-like, have every the trend of closing the bone piece that not yet the contacts hypertrophy increase that rises appreciably in the hyperosteogeny at adjacent cone edge.
4 degree " bony spur ' cause " bone bridge " irregularly shaped.
At present the western drug of this disease for the treatment of is a lot, as: ibuprofen, English are too clear etc., although their can respite slight illness, quick result, can not eradicate sufferer, and itself and long-term taking Western medicine can impairing the liver, be impairment of the kidney.
Summary of the invention
The present invention be directed to traditional treatment hyperosteogeny disease drug and have the defect of a lot of side effect, provide that a kind of therapeutic effect is good, side effect is little, and the medicine of the treatment bone matrix hyperplasia of being made by pure Chinese medicine.
The technical scheme that realizes the employing of foregoing invention object is: a kind of medicine for the treatment of bone matrix hyperplasia, this medicine is made up of the pure Chinese medicine of following weight portion: Flos Carthami, Herba speranskiae tuberculatae, the each 2-3 part of Herba Lycopodii, Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, the each 3-4 part of Fructus Chaenomelis.
As preferred version, this medicine is made up of the pure Chinese medicine of following weight portion: each 3 parts of Flos Carthami, Herba speranskiae tuberculatae, Herba Lycopodii, each 4 parts of Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, Fructus Chaenomelis.
As preferred version, each drug component grinds to form after mixing according to weight portion during fine powder incapsulates, and the medicated powder weight in every capsules is 1 gram, makes medicament capsule.
Compared with traditional western medicine, the medicine of this treatment bone matrix hyperplasia disclosed in this invention is made up of pure Chinese medicine, medicine source is abundant, chemical substance simple for production, not add any other, side effect is minimum, long-term taking is very little even without injury to human injury, therapeutic effect is obvious, and each important in medicine can blood circulation promoting and blood stasis dispelling, expelling wind and removing dampness, invigorating the liver and kidney, bone and muscle strengthening, to reach the object for the treatment of hyperosteogeny.
The medicine for the treatment of hyperosteogeny disclosed in this invention, makes by mostly being Chinese medicine, and the pharmacological action of each Chinese medicine is as follows:
The Radix Angelicae Sinensis hemopoietic blood stasis dispelling of invigorating blood circulation;
Herba speranskiae tuberculatae, Herba Lycopodii, the removing dampness of Ramulus Cinnamomi dispelling wind, relaxing muscles and tendons and activating QI and blood in the collateral;
Rhizoma Cibotii, Radix Dipsaci enriching kidney essence and strengthening bone and muscle;
Radix Aconiti (processed), by cold warming the meridian, dispels the wind to stop Persistent Pain;
Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, dispelling wind and removing obstruction in the collateral, dampness removing is with detumescence;
Flos Carthami blood circulation promoting and blood stasis dispelling, detumescence;
Radix Achyranthis Bidentatae, the Fructus Chaenomelis soft muscle that dehumidifies, dredging collateral is invigorated blood circulation.
The specific embodiment
Below in conjunction with drawings and Examples, the present invention will be further described.
Disclosed in this invention is a kind of medicine for the treatment of bone matrix hyperplasia, this medicine is made up of the pure Chinese medicine of following weight portion: each 20 grams of Flos Carthami, Herba speranskiae tuberculatae, Herba Lycopodii, each 40 grams of Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, Fructus Chaenomelis.
This medicine is made up of the pure Chinese medicine of following weight portion: each 25 grams of Flos Carthami, Herba speranskiae tuberculatae, Herba Lycopodii, each 30 grams of Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, Fructus Chaenomelis.
This medicine is made up of the pure Chinese medicine of following weight portion: each 30 grams of Flos Carthami, Herba speranskiae tuberculatae, Herba Lycopodii, each 38 grams of Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, Fructus Chaenomelis.
As preferred version, this medicine is made up of the pure Chinese medicine of following weight portion: each 30 grams of Flos Carthami, Herba speranskiae tuberculatae, Herba Lycopodii, each 40 grams of Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, Fructus Chaenomelis.
As preferred version, each drug component grinds to form after mixing according to weight portion during fine powder incapsulates, and the fineness of grind of general fine drug powder is 50 orders.Medicated powder weight in every capsules is 1 gram, makes medicament capsule.
It is directly edible that this medicine liquid can be served as medicine powder.
Instructions of taking is: warm water takes after the meal, every day three times, each 5, amounts to 5 grams.Take medicine and within 7-14 days, can make the state of an illness take a turn for the better to some extent, various symptoms all alleviate to some extent, and patient is almost recovered after taking medicine 2 months.
Clinical observation result of the test of the present invention:
Case load 216, wherein treatment group 136 examples, matched group 80 examples.
Physical data, treatment group 136 examples, male's 71 examples, women's 65 examples, age 34-70 year, disease time 1 year-10 years.
Contrast 1 group of 38 example, male's 18 examples, women's 20 examples, age 35-68 year, disease time: 1 year-9 years.
Contrast 2 group of 42 example, male's 22 examples, women's 20 examples, age 31-69 year, disease time: 1 year-12 years.
Treatment group and the comparison of matched group curative effect:
Group:
Treatment group:
Number of cases: 136 examples
Effective number of cases: 93 examples, obvious effective rate 69.1%
Effectively number of cases: 37
Invalid number of cases: 6
Total effectively number of cases: 136
Matched group 1:
Number of cases: 38 examples
Effective number of cases: 9 examples, obvious effective rate 23.7%
Effectively number of cases: 21 examples
Invalid number of cases: 6 examples
Total effectively number of cases: 30 examples
Matched group 2:
Number of cases: 42 examples
Effective number of cases: 8 examples, obvious effective rate 19.1%
Effectively number of cases: 18 examples
Invalid number of cases: 5 examples
Total effectively number of cases: 26 examples
Treatment group and matched group have significant difference.
The average course for the treatment of of treatment group 8 weeks, contrasts the average course for the treatment of 8 weeks of 1,2 group.
Model case:
Example 1, Wang, female, 65 years old, the peasant of Yutian County of Hebei province, suffered from bone matrix hyperplasia 6 years, failed to cure through multi-treatment, and rear use takes 3 times for of the present invention day, and each 5, to take 5 weeks, basic healing is not recurrence so far.
Example 2, Lee, 57 years old, man, the teacher of Yutian County of Hebei province, suffers from bone matrix hyperplasia 3 years, takes the present invention, and day takes 3 times, and each 5, the 1 week state of an illness of taking medicine takes a turn for the better to some extent, takes altogether 4 weeks basic healings.
Example 3, Zhang, man, 61 years old, people from Tianjin, suffered from bone matrix hyperplasia 3 years, fail to cure through multi-treatment, after take the present invention, day take 3 times, each 5, take 6 weeks basic healings, do not recur so far.
Taboo: glaucoma patient is prohibited clothes
Disclosed is above only specific embodiments of the invention, but the present invention is not limited thereto, and the changes that any person skilled in the art can think of, within all should dropping on protection scope of the present invention.
Claims (3)
1. treat the medicine of bone matrix hyperplasia for one kind, it is characterized in that, this medicine is made up of the pure Chinese medicine of following weight portion: Flos Carthami, Herba speranskiae tuberculatae, the each 2-3 part of Herba Lycopodii, Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, the each 3-4 part of Fructus Chaenomelis.
2. according to the medicine of the treatment bone matrix hyperplasia described in claim 1, it is characterized in that, this medicine is made up of the pure Chinese medicine of following weight portion: each 3 parts of Flos Carthami, Herba speranskiae tuberculatae, Herba Lycopodii, each 4 parts of Radix Angelicae Sinensis, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Rhizoma Cibotii, Radix Dipsaci, Radix Aconiti (processed), Rhizoma Dioscoreae Septemlobae, Radix Gentianae Macrophyllae, Radix Achyranthis Bidentatae, Fructus Chaenomelis.
3. according to the medicine of the treatment bone matrix hyperplasia described in claim 1, it is characterized in that, each drug component grinds to form after mixing according to weight portion during fine powder incapsulates, and makes every medicament capsule containing 1 gram of medicated powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210034160.9A CN102772617B (en) | 2012-02-16 | 2012-02-16 | Medicine for treating disease of hyperosteogeny |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210034160.9A CN102772617B (en) | 2012-02-16 | 2012-02-16 | Medicine for treating disease of hyperosteogeny |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102772617A CN102772617A (en) | 2012-11-14 |
| CN102772617B true CN102772617B (en) | 2014-05-14 |
Family
ID=47117874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210034160.9A Expired - Fee Related CN102772617B (en) | 2012-02-16 | 2012-02-16 | Medicine for treating disease of hyperosteogeny |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772617B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138243A (en) * | 2015-04-08 | 2016-11-23 | 潘思熹 | A kind of medicine of foot bath treatment hyperosteogeny |
| CN106620613A (en) * | 2016-12-26 | 2017-05-10 | 广州智润生物制药科技有限公司 | Medicine for treating hyperosteogeny and its preparing process |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145798A (en) * | 1996-07-03 | 1997-03-26 | 陈洁 | Medicine for curing prolapse of lumbar intervertebral disc and its use |
| CN101112537A (en) * | 2007-08-15 | 2008-01-30 | 陈玉龙 | Chinese traditional medicine preparations for treating hyperosteogeny disease |
| CN101411802A (en) * | 2008-11-21 | 2009-04-22 | 赵献民 | Black plaster for treating hyperosteogeny and preparation method thereof |
-
2012
- 2012-02-16 CN CN201210034160.9A patent/CN102772617B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145798A (en) * | 1996-07-03 | 1997-03-26 | 陈洁 | Medicine for curing prolapse of lumbar intervertebral disc and its use |
| CN101112537A (en) * | 2007-08-15 | 2008-01-30 | 陈玉龙 | Chinese traditional medicine preparations for treating hyperosteogeny disease |
| CN101411802A (en) * | 2008-11-21 | 2009-04-22 | 赵献民 | Black plaster for treating hyperosteogeny and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 中医治疗膝骨性关节炎体会;刘首芳等;《河南中医》;20120131;第32卷(第1期);第74-75页 * |
| 中医药综合治疗膝骨关节炎研究进展;张弢;《中医药临床杂志》;20110531;第23卷(第5期);第467-470页 * |
| 刘首芳等.中医治疗膝骨性关节炎体会.《河南中医》.2012,第32卷(第1期),第74-75页. |
| 张弢.中医药综合治疗膝骨关节炎研究进展.《中医药临床杂志》.2011,第23卷(第5期),第467-470页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102772617A (en) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766773B (en) | Chinese medicine prescription for treating talagia | |
| CN100506274C (en) | Traditional Chinese medicine for treating cervical vertebra disease | |
| CN104398982A (en) | Traditional Chinese medicine composition for treating traumatic injury and joint pain and swelling | |
| CN103893702A (en) | Traditional Chinese medicine composition for treating cervical spine bone hyperplasia and preparation method thereof | |
| CN103520579A (en) | Medicinal liquor used for treating lumbocrural pain, hyperostosis and sciatica | |
| CN102293853B (en) | Chinese medicinal pills for treating Bi syndrome | |
| CN100372551C (en) | Chinese medicine for treating hyperosteogeny | |
| CN102772617B (en) | Medicine for treating disease of hyperosteogeny | |
| CN102266542B (en) | Ointment patch for treating hyperosteogeny and preparation method thereof | |
| CN101912536B (en) | Medicinal composition for treating rheumatism and rheumatoid disease | |
| CN101703662A (en) | Oral Chinese medicament for treating hyperosteogeny | |
| CN101167911A (en) | Plaster for treating hyperosteogeny and invertebral disc protrusion | |
| CN105688059A (en) | Traditional Chinese medicine preparation with folium artemisiae argyi for treating osteoproliferation through external application | |
| CN102600316B (en) | Chinese medicinal herb preparation for treating closed injury and preparation method thereof | |
| CN102552843B (en) | Medicament composite for curing osteoarthropathy | |
| CN102125612B (en) | Chinese medicinal preparation for treating acute lumbar sprain | |
| CN101301394B (en) | Medicament for treating rheumatoid disease | |
| CN100339095C (en) | Cervical spondylosis treating Chinese medicine composition | |
| CN101129718B (en) | Traditional Chinese medicine preparation for treating leuoderma | |
| CN110507796A (en) | A kind of Chinese medicine preparation for treating a variety of diseases | |
| CN104258308A (en) | Traditional Chinese medicine preparation for treating cholelithiasis | |
| CN103070997A (en) | Drug for curing ischialgia and preparing method thereof | |
| CN102824471B (en) | Traditional Chinese medicine drug for treating spinal disc herniation, sciatica and leg pain | |
| CN104107252A (en) | Folium artemisiae argyi powder | |
| CN104474353A (en) | Medicine for treating myasthenia gravis and preparation method of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140514 Termination date: 20170216 |